Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (NSCLC)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)UnknownNCT01843647
What this trial is testing

Neoadjuvant Therapy of Icotinib in Epidermal Growth Factor Receptor Mutated NSCLC Patients

Who this might be right for
Non-small-cell Lung Cancer
Betta Pharmaceuticals Co., Ltd. 100
Not applicableUnknownNCT04391283
What this trial is testing

First Line Osimertinib for EGFR Mutation-positive Non-Small Cell Lung Cancer in Real World Chinese Setting

Who this might be right for
Carcinoma, Non-Small-Cell Lung
First Affiliated Hospital of Zhejiang University 500
Testing effectiveness (Phase 2)UnknownNCT01714908
What this trial is testing

Phase II Study of Erlotinib With Concurrent Radiotherapy in Unresectable NSCLC With Activating Mutation of EGFR in Exon 19 or 21

Who this might be right for
Non-small Cell Lung Cancer
Jinming Yu 100
Early research (Phase 1)Ended earlyNCT02206763
What this trial is testing

Erlotinib and Momelotinib for the Treatment of Epidermal Growth Factor Receptor (EGFR) Mutated EGFR Tyrosine Kinase Inhibitor (TKI) Naive Metastatic Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
EGFR Mutated EGFR TKI Naive Metastatic NSCLC
Sierra Oncology LLC - a GSK company 11
Not applicableStudy completedNCT01081496
What this trial is testing

Epidemiological Study to Evaluate the Prevalence of Epidermal Growth Factor Receptor (EGFR) Mutation Status in Patients With Newly Diagnosed Locally Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC)

Who this might be right for
Non Small Cell Lung Cancer
AstraZeneca 1,000
Not applicableUnknownNCT04304638
What this trial is testing

Real-world Treatment Patterns and Clinical Outcomes in EGFR-mutant Unresectable Locally Advanced NSCLC

Who this might be right for
Non Small Cell Lung CancerStage III Non-small-cell Lung CancerEGFR Mutation-Related Tumors
Chinese Academy of Medical Sciences 450
Testing effectiveness (Phase 2)Active Not RecruitingNCT04027647
What this trial is testing

Phase 2 Study of Dacomitinib in NSCLC

Who this might be right for
NSCLC Stage IIIBNSCLC Stage IIICNSCLC Stage IV+2 more
National Cancer Centre, Singapore 118
Large-scale testing (Phase 3)Active Not RecruitingNCT05388669
What this trial is testing

Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer

Who this might be right for
Advanced or Metastatic Non-small Cell Lung Cancer
Janssen Research & Development, LLC 418
Early research (Phase 1)Study completedNCT02947386
What this trial is testing

Nimotuzumab and Nivolumab in Treating Patients With Advanced Non-small Cell Lung Cancer

Who this might be right for
EGFR Gene MutationRecurrent Non-Small Cell Lung CarcinomaStage IIIA Non-Small Cell Lung Cancer+2 more
Roswell Park Cancer Institute 7
Not applicableStudy completedNCT02131259
What this trial is testing

Long-term Observation PMS for Afatinib

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Boehringer Ingelheim 1,605
Not applicableStudy completedNCT04552613
What this trial is testing

Efficacy of Targeted Therapy Combined Chemotherapy in Advanced EGFR Positive NSCLC Patients

Who this might be right for
Non-small-lung-cell CancerNSCLCEGFR Gene Mutation
The Fourth Affiliated Hospital of Zhejiang University School of Medicine 114
Testing effectiveness (Phase 2)UnknownNCT02036359
What this trial is testing

Erlotinib Monotherapy Versus Docetaxel and Cisplatin as Neoadjuvant Therapy in Patients of stageIIIA Lung ca

Who this might be right for
Non-small Cell Lung Cancer(NSCLC)
National Taiwan University Hospital 76
Testing effectiveness (Phase 2)Looking for participantsNCT05104788
What this trial is testing

Icotinib With Chemotherapy as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
Peking University Cancer Hospital & Institute 27
Early research (Phase 1)Study completedNCT03446417
What this trial is testing

ZN-e4 in Subjects With Epidermal Growth Factor Receptor Mutated Non-Small Cell Lung Cancer

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Zeno Pharmaceuticals, Inc. 34
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06319950
What this trial is testing

High-dose Furmonertinib Versus Osimertinib in Advanced EGFRm NSCLC Patients With Brain Metastases

Who this might be right for
Lung Cancer, Nonsmall Cell
Taizhou Hospital 255
Testing effectiveness (Phase 2)Study completedNCT02442349
What this trial is testing

Phase II Single Arm Study of AZD9291 to Treat NSCLC Patients in Asia Pacific

Who this might be right for
Non-Small Cell Lung Cancer
AstraZeneca 171
Not applicableActive Not RecruitingNCT06538038
What this trial is testing

Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients

Who this might be right for
Non Small Cell Lung CancerEpidermal Growth Factor Receptor Gene MutationStage III Lung Cancer+1 more
PrECOG, LLC. 200
Not applicableActive Not RecruitingNCT06376084
What this trial is testing

Osimertinib With Chemotherapy as First-line Therapy for EGFR Mutation-positive NSCLC

Who this might be right for
Carcinoma, Non-Small-Cell LungLung NeoplasmsRespiratory Tract Neoplasms+7 more
AstraZeneca 532
Testing effectiveness (Phase 2)UnknownNCT01470716
What this trial is testing

Neoadjuvant Erlotinib for Operable Stage II or IIIA NSCLC With EGFR Mutations

Who this might be right for
NSCLC Stage IINSCLC, Stage IIIA
National Cancer Center, Korea 26
Testing effectiveness (Phase 2)Ended earlyNCT03505710
What this trial is testing

DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing or -Mutated Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
Daiichi Sankyo 181
Next Page